Description
Mechanism: DPP-4 Resistance & Albumin Binding
Semaglutide owes its distinct pharmacological profile to specific structural modifications that overcome the rapid degradation seen in native GLP-1.
-
Amino Acid Substitution: The substitution of Alanine with α-aminoisobutyric acid (Aib) at position 8 renders the peptide resistant to degradation by the enzyme dipeptidyl peptidase-4 (DPP-4).
-
Albumin Affinity: The critical innovation is the acylation of the peptide backbone with a C-18 fatty diacid side chain. This spacer allows Semaglutide to bind non-covalently to serum albumin with high affinity.
-
Extended Half-Life: This albumin binding serves a dual purpose: it shields the peptide from renal clearance and enzymatic breakdown, extending the plasma half-life to approximately 7 days (165 hours) in research models.
This research peptide undergoes rigorous quality control and stability testing to ensure maximum integrity for scientific applications. Each batch is manufactured under strict laboratory conditions and verified through independent laboratory analysis.
⚠️ FOR RESEARCH PURPOSES ONLY
This product is strictly for in-vitro laboratory research, analysis, and development. It is not intended for human consumption, injection, or therapeutic use. Semaglutide is not a drug, dietary supplement, or food. It is a research chemical. All statements regarding the physiological mechanisms of Semaglutide are based on preclinical animal and cell-culture studies and are provided for educational and informational purposes only.
Primary Research Targets
Semaglutide is the primary subject of study for the following physiological pathways:
-
Glucose-Dependent Insulin Secretion: Investigating the stimulation of pancreatic beta-cells to release insulin only when glucose levels are elevated.
-
Glucagon Suppression: Studying the inhibition of inappropriate glucagon secretion from alpha-cells.
-
Gastric Motility: Analyzing the delay in gastric emptying rates, a mechanism linked to satiety signaling via the Vagus nerve.
The “Control Standard” for Comparative Studies: In the current landscape of metabolic research, Semaglutide serves as the Control Standard. It is the baseline against which the efficacy of novel “Twin” (Tirzepatide) and “Triple” (Retatrutide) agonists are measured in preclinical trials.
Technical Specifications
-
CAS Number: 910463-68-2
-
Molecular Formula: C₁₈₇H₂₉₁N₄₅O₅₉
-
Molar Mass: 4113.58 g/mol
-
Sequence: Modified GLP-1 (7-37) backbone with C-18 fatty acid chain
-
Purity: ≥99% (HPLC Verified)
-
Form: Lyophilized White Powder




















